Get ESTROGEL®
	
    
        ESTROGEL® 0.06% (estradiol gel) is available nationwide. Most insurance plans cover it (with a co-pay)
        although you may save money by checking EstroGel cash prices on the following websites:
    
        
        ESTROGEL® 0.06% (estradiol gel) is available nationwide. Most insurance plans cover it (with a co-pay)
        although you may save money by checking EstroGel cash prices on the following websites:
    
Reduce moderate to severe hot flashes  | 
					
Treat moderate to severe menopausal changes in and around the vagina*  | 
					
| * | If you use EstroGel only to treat menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.1 | 
You and your healthcare provider should talk regularly about whether you still need treatment with EstroGel to control these problems.
				FDA-approved bioidentical estrogen therapy gel1,4
				Delivers a consistent, effective dose1*
| * | Efficacy was assessed at 4 and 12 weeks. | 
				Clear, dries in 2 to 5 minutes, odorless when dry1
			FDA-approved bioidentical estrogen therapy gel1,4
			Delivers a consistent, effective dose1*
| * | Efficacy was assessed at 4 and 12 weeks. | 
			Clear, dries in 2 to 5 minutes, odorless when dry1
Speak up about your symptoms of menopause. Make an appointment today. Some symptoms of menopause, though not all, can be reduced or treated with EstroGel.1 Talk with your healthcare provider about your treatment options and whether a prescription for EstroGel is right for you.
Want more information about EstroGel?
Ready to plan for your appointment?
Did you know you can save up to $35 on your EstroGel prescription?
References: 1. EstroGel [package insert]. Morristown, NJ: ASCEND Therapeutics; 2023. 2. The Office on Women’s Health. Top Questions About Menopause. Washington, DC; US Department of Health and Human Services; August 2017. 3. Food and Drug Administration. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—recommendations for clinical evaluation. Draft guidance. Washington, DC; US Department of Health and Human Services; January 2003. 4. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011;86(7):673-680.